

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

NOVO NORDISK INC. and NOVO
NORDISK A/S,

Plaintiffs,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant.

C.A. No. 1:22-cv-23-JPB

**MYLAN PHARMACEUTICALS INC.'S
RULE 7.1 DISCLOSURE STATEMENT**

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, defendant Mylan
Pharmaceuticals Inc. hereby states that:

1. Mylan Pharmaceuticals Inc. is a wholly-owned subsidiary of Mylan Inc. and operates as a distinct corporate entity;
3. Mylan Inc. is wholly owned by Viatriis Inc., a publicly-traded company, and operates as a distinct corporate entity; and
4. No publicly-held company owns 10% or more of Viatriis Inc.'s stock.

Dated: April 8, 2022

By: /s/ Brandon M. White

Brandon M. White (WV Bar No. 14021)
PERKINS COIE LLP
700 13th Street NW
Suite 800
Washington, DC 20005
Tel: (202) 654-6200
bmwhite@perkinscoie.com

Counsel for Mylan Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

I certify that on this 8th day of April 2022, I electronically filed the foregoing “Mylan Pharmaceuticals Inc.’s Rule 7.1 Disclosure Statement” with the Clerk of the Court using the CM/ECF system, which will send notice of the same to the following counsel of record:

James F. Companion
Sandra K. Law
jfc@schraderlaw.com
skl@schraderlaw.com
Schrader Companion Duff & Law, PLLC
401 Main Street
Wheeling, WV 26003

Jeffrey J. Oelke
Ryan P. Johnson
Robert E. Counihan
Laura T. Moran
FENWICK & WEST LLP
902 Broadway, Suite
14 New York, NY 10010

Counsel for Plaintiffs

/s/ Brandon M. White
Brandon M. White (WV Bar No. 14021)
PERKINS COIE LLP
700 13th Street NW
Suite 800
Washington, DC 20005
Tel: (202) 654-6200
bmwhite@perkinscoie.com

Counsel for Mylan Pharmaceuticals Inc.